e faecium nr  (ATCC)

Journal: Scientific Reports

Article Title: Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci

doi: 10.1038/s41598-025-29583-1

Figure Lengend Snippet: Description and MICs (μM) of potent antibacterial library hits against E. faecium NR-31909.

Article Snippet: Fig. 6 Multistep resistance selection of ridinilazole, CRS3123, and rifampicin against Enterococcus species. (A) E. faecalis ATCC 29,212 and (B) E. faecium NR-31,909 were serially passaged over a 10-day period in the presence of ridinilazole, CRS3123, or rifampicin.

Techniques: Activity Assay, Virus

Journal: Scientific Reports

Article Title: Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci

doi: 10.1038/s41598-025-29583-1

Figure Lengend Snippet: Time kill assay of ridinilazole, CRS3123 and linezolid at 5× and 10× MIC, against E. faecium NR-31,909. Samples treated with DMSO were used as negative control. The results are given as means ± SD ( n = 3; data without error bars indicate that the SD is too small to be seen).

Article Snippet: Fig. 6 Multistep resistance selection of ridinilazole, CRS3123, and rifampicin against Enterococcus species. (A) E. faecalis ATCC 29,212 and (B) E. faecium NR-31,909 were serially passaged over a 10-day period in the presence of ridinilazole, CRS3123, or rifampicin.

Techniques: Time-Kill Assay, Negative Control

Journal: Scientific Reports

Article Title: Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci

doi: 10.1038/s41598-025-29583-1

Figure Lengend Snippet: Multistep resistance selection of ridinilazole, CRS3123, and rifampicin against Enterococcus species. (A) E. faecalis ATCC 29,212 and (B) E. faecium NR-31,909 were serially passaged over a 10-day period in the presence of ridinilazole, CRS3123, or rifampicin. The MICs of each compound were determined daily using the broth microdilution method.

Article Snippet: Fig. 6 Multistep resistance selection of ridinilazole, CRS3123, and rifampicin against Enterococcus species. (A) E. faecalis ATCC 29,212 and (B) E. faecium NR-31,909 were serially passaged over a 10-day period in the presence of ridinilazole, CRS3123, or rifampicin.

Techniques: Selection

Journal: Scientific Reports

Article Title: Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci

doi: 10.1038/s41598-025-29583-1

Figure Lengend Snippet: In vivo efficacy of ridinilazole and CRS3123 against Enterococcus infection in the C. elegans model. C. elegans were infected with E. faecium NR-31,909 or E. faecalis ATCC 29,212. After infection, 30 worms were treated with ridinilazole, CRS3123, or linezolid. After 24 h, worms were lysed, and bacteria were plated to determine CFU counts. In E. faecium -infected worms, CRS3123 and linezolid reduced bacterial burden by approximately 3.8 and 3.5 log units, respectively, while ridinilazole produced a 2.5 log reduction. In E. faecalis -infected worms, CRS3123 and linezolid resulted in 1.8 and 1.5 log reductions, whereas ridinilazole showed no significant effect. Results are expressed as means from three biological replicates ± standard deviation. Statistical analyses were determined by one-way ANOVA with post hoc testing (* p < 0.01, ** p < 0.005, *** p < 0.0001).

Article Snippet: Fig. 6 Multistep resistance selection of ridinilazole, CRS3123, and rifampicin against Enterococcus species. (A) E. faecalis ATCC 29,212 and (B) E. faecium NR-31,909 were serially passaged over a 10-day period in the presence of ridinilazole, CRS3123, or rifampicin.

Techniques: In Vivo, Infection, Bacteria, Produced, Standard Deviation